Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACCESS-I: Low-dose Pembrolizumab + Chemotherapy in Cervical Cancer
NCT06670911Phase 2Recruiting
- Sponsor
- Instituto Nacional de Câncer José Alencar Gomes da Silva
- Start
- Feb 2025
- Primary completion
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in Cervical Cancer (CC), sponsored by Instituto Nacional de Câncer José Alencar Gomes da Silva. Started Feb 2025; status: recruiting.
02
Drugs
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06670911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06670911.